Micromet Inc
Micromet Inc is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Micromet Inc.
Micromet Inc is a company.
Key people at Micromet Inc.
Key people at Micromet Inc.
Micromet Inc. was a biopharmaceutical company specializing in innovative antibody-based therapies for cancer, inflammation, and autoimmune diseases, with a focus on its proprietary BiTE® (Bispecific T-cell Engager) technology.[1][2][5] It developed molecules like blinatumomab, a lead candidate targeting CD19 on B-lymphocytes to direct T cells against cancers such as acute lymphoblastic leukemia (ALL) and non-Hodgkin's lymphoma (NHL), serving patients with relapsed/refractory blood cancers.[2][3][5] The company solved the challenge of engaging the immune system's T cells to precisely kill tumor cells, addressing limitations of traditional antibodies that couldn't effectively bind T cells.[5] Micromet showed strong growth momentum through clinical advancements—blinatumomab reached Phase 2 for ALL minimal residual disease and Phase 1 for NHL—culminating in its 2012 acquisition by Amgen for $1.16 billion.[2][3][5]
Micromet originated as a spinoff from the immunology department of Munich University in the early 1990s, formally incorporated in 1998 (with founding noted as 1993 in some records).[1][4][6] It began as a cancer diagnostics firm but pivoted to developing antibody pipelines amid the era's antibody boom, alongside peers like Genmab and Medarex.[1] Backed by top venture capitalists, it raised ~$60 million in rounds from 1996-2001, focusing initially on assets like MT201, then exploring BiTE technology as a secondary but potent platform.[1] Funding challenges arose as lead molecules lacked proof-of-concept; in 2006, it reverse-merged into U.S. public company Cancervax, entering public markets with ~$30 million cash and a $120 million valuation despite prior ~$100 million raised.[1] Micromet's team led the combined entity, later raising another $30 million, building toward BiTE breakthroughs and the Amgen deal.[1][2]
Micromet rode the early 2000s biologics revolution, particularly bispecific antibodies and immunotherapy, timing perfectly with rising interest in T-cell engagers amid antibody tech maturation (e.g., fully human antibodies from Abgenix/CAT).[1][5] Market forces like venture funding for platform tech, public market access via reverse mergers, and big pharma's hunger for oncology pipelines propelled it—BiTE addressed unmet needs in hematologic cancers where chemo failed.[1][2][3] It influenced the ecosystem by pioneering BiTE, now integrated into Amgen's research site in Munich (formerly Micromet's), accelerating therapies like blinatumomab (approved post-acquisition as Blincyto) and validating European biotech's global impact.[4][5]
Post-2012 acquisition, Micromet's legacy endures through Amgen's expansion of BiTE technology into broader oncology, with blinatumomab commercialized and new engagers in development.[4][5] Trends like immuno-oncology dominance, combination therapies, and solid-tumor BiTE applications will shape its influence, potentially via Amgen's pipeline milestones and royalties from licensees.[2][3] As biotech consolidates, Micromet exemplifies how university spinouts scale via tech platforms, priming Amgen to evolve BiTE into a multi-product franchise amid precision medicine's rise—echoing its origins as a Munich immunology bet that delivered breakthrough cancer tools.[1][5]
